Axatilimab

艾克利单抗

Report date: 2026/04/10 20:01:49

Base Information

Drug NameAxatilimab
Drug Alias NameAxatilamabAxatilimab-csfrNIKTIMVOSNDX-6352UCB-6352 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsSolid tumoursCytokine Release SyndromeGraft vs Host Disease +[18] 
Global Approved IndicationsGraft vs Host Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/08/14
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityDana-Farber Cancer InstituteIncyte Biosciences (Shanghai) Co Ltd +[10] 
Inactive CompaniesUniversity Of Miami
Active IndicationsSolid tumoursGraft vs Host DiseaseMyeloproliferative Disorders +[13] 
Inactive IndicationsCytokine Release SyndromeRespiratory Distress Syndrome, AdultNeoplasm Metastasis +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG